← FDA DRUG APPROVALS

FDA ANDA · ANDA074473

TOLMETIN SODIUM

Sponsor: RISING

APPLICATION
ANDA074473
TYPE
ANDA
ORIGINAL APPROVAL
1994-08-30
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

TOLMETIN SODIUMPrescription
TOLMETIN SODIUM EQ 600MG BASE · TABLET · ORAL

Approval history

2024-11-21Labeling · Supplement 18 · standardAP
2023-08-31Manufacturing (CMC) · Supplement 17 · unknownAP
2021-04-28Labeling · Supplement 15 · standardAP
2016-05-09Labeling · Supplement 12 · standardAP
2008-07-25Labeling · Supplement 9AP
2006-09-22Labeling · Supplement 6AP
2000-08-02Manufacturing (CMC) · Supplement 4AP
1999-04-30Manufacturing (CMC) · Supplement 3AP
1999-04-30Manufacturing (CMC) · Supplement 2AP
1995-02-01Manufacturing (CMC) · Supplement 1AP
1994-08-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →